We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Multaq Not Safe for Use in Subgroup of AF Patients
FDA: Multaq Not Safe for Use in Subgroup of AF Patients
December 30, 2011
The FDA is requiring a boxed warning for Sanofi-Aventis’ atrial fibrillation (AF) treatment Multaq in patients with permanent AF after a safety review showed a higher risk of cardiovascular (CV) death.